Study of AHB-171 for stable chronic hepatitis B
Treatments studied
Part of Digestive system, Infections clinical trials.
This trial tests a new investigational drug called AHB-171 for people with chronic hepatitis B who are already stable on standard antiviral therapy. It aims to see if the drug is safe and may help control the virus better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been taking a stable hepatitis B medication (nucleoside analog) for at least 6 months.
- Your hepatitis B surface antigen (HBsAg) level is between 100 and 3,000 IU/mL and your HBV DNA is less than 100 IU/mL.
- You do not have advanced liver disease like cirrhosis, liver cancer, or varices.
- You are not pregnant, breastfeeding, or planning to become pregnant, and you agree to use effective contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injection called SA1211 for people with chronic hepatitis B. It will help see if the treatment is safe and how it works in the body.
This study tests a new experimental drug called AHB-171 in people with chronic hepatitis B infection. The trial aims to see how safe the drug is and how well it works to help control the virus.
This study tests whether a new drug called AHB-171 can help treat chronic hepatitis B (a long-term liver infection). You would receive the drug by injection under your skin and be monitored to see if it helps reduce the hepatitis B virus and improves liver health.
This trial tests a new injection called AHB-137 for people with chronic hepatitis B. It aims to see if the drug is safe and helps control the virus.
This trial tests a new drug, AHB-137, in people with chronic hepatitis B who are already on a stable antiviral treatment. It aims to see if AHB-137 can help lower the virus further or improve outcomes.
This study tests a new medicine called AHB-137 for people with chronic hepatitis B who are HBeAg negative and currently on antiviral therapy. The goal is to see if it can help control the virus better or allow you to stop your current medication safely.
Hear when a new Chronic Hepatitis B Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.